With Myriad Sure To Appeal, Gene-Patent Case Casts Potential Shadows
Executive Summary
On March 29, Justice Robert Sweet of the Southern District Court of New York made the controversial decision to invalidate parts of seven patents owned by Myriad Genetics Inc. and the University of Utah Research Foundation, cheering opponents of the established practice of patenting gene sequences. It’s only the first step in a case that is almost certain to reach the US Supreme Court, but it might soon be eclipsed by a patent case currently before the Court, Bilski v. Kappos, which could have a much deeper effect on biotech business.
You may also be interested in...
Market & Industry Briefs
Brief summaries of recent medtech market and industry developments. This month we cover the transcatheter heart valve market, clinical results on Eurocor's DIOR drug-eluting balloon, additions to Covidien's endomechanical business, and patent disputes in diagnostics.
Market & Industry Briefs
Brief summaries of recent medtech market and industry developments. This month we cover the transcatheter heart valve market, clinical results on Eurocor's DIOR drug-eluting balloon, additions to Covidien's endomechanical business, and patent disputes in diagnostics.
PTO Creates Task Force To Respond To Upcoming Bilski Decision
PTO wants government to back Myriad in its appeal of gene patent ruling, agency's Arti Rai says at BIO IP conference. PTO seeks to reduce patent pendency through patent reform and a fast-track review option.
Need a specific report? 1000+ reports available
Buy Reports